4425-15-4

Upstream product

• 1701-57-1 2,3,4,5-tetrahydro-1Hbenzo[b]azepine 
• 302-17-0 chloral hydrate 
• 7647-01-0 hydrogenchloride 
• 79-37-8 oxalyl dichloride 
• 34849-23-5 oxo-(2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetyl chloride 
• 134-20-3 2-carbomethoxyaniline 
• 74799-85-2 N-(3-methoxycarbonyl-propyl)-N-methyl-anthranilic acid methyl ester 
• 857601-81-1 N-(3-methoxycarbonyl-propyl)-anthranilic acid methyl ester 
• 3749-11-9 1-methyl-3,4-dihydro-1H-benzo[b]azepin-5(2H)-one 
• 4424-80-0 2,3,4,5-tetrahydro-1H-1-benzo[b]azepin-2-one 
• 20642-90-4 1-methyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine 

Relevant academic research and scientific papers

COMPOUNDS SUITABLE AS MODULATORS OF HDL

Disclosed herein in the embodiments of the present invention are the compounds suitable as modulators of HDL having general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

COMPOUNDS SUITABLE AS MODULATORS OF HDL

Disclosed herein in the embodiments of the present invention are the compounds suitable as modulators of HDL having general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

Cyclic anthranilic acid derivatives and process of preparing the same

The following cyclic anthranilic acid derivative, their acid addition salts or alkali salts thereof represented by a general formula [I] are useful for antirheumatic drug, autoimmune disease curing drug and metabolic bone disease curing drug. STR1 wherein R1 to R6 and X are as defined in claim 1.